WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a research service agreement with Germany’s BioNTech (NASDAQ: BNTX).
As part of the collaboration, WuXi Bio will leverage its patented technology platform to develop antibodies targeting two undisclosed targets for BioNTech, aimed at advancing next-generation candidate drugs. WuXi will receive an upfront payment of $20 million and will also be eligible for additional undisclosed milestone payments related to research and development, regulatory filings, and commercialization, along with tiered royalties on sales.
This agreement marks BioNTech’s sixth partnership with a China-based firm since the beginning of 2023, following collaborations with Suzhou Medilink Therapeutics, Biotheus Biotechnology, and Duality Biologics, among others.- Flcube.com
